Bio-Rad Launches New ProteOn GLH Sensor Chip for Small Molecule Applications
HERCULES, CA — June 30, 2008 — Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostics products, today announced a new GLH sensor chip for its ProteOn™ XPR36 protein interaction array system. The chip, which generates a high analyte signal through its high ligand activity and binding capacity, is expected to deliver an improved surface plasmon resonance (SPR) signal compared to other commercially available surfaces. The amine coupling chemistry and polymer layer of the GLH sensor chip is similar to the ProteOn GLC and GLM chips, allowing exceptional ligand binding across a wide pH range.
"Customers who require high sensitivity detection can benefit significantly from using the GLH sensor chip and our ProteOn XPR36 protein interaction array system, especially for any small protein molecule or protein-protein research where the analyte response is low," said Renee LeMaire-Adkins, Ph.D., Bio-Rad Marketing Manager, Protein Interaction Technology.
The ProteOn GLH sensor chip, consisting of a highly extended mixed polymer layer for maximum binding capacity, is designed for general amine coupling. The chip is optimized for protein-small molecule interactions as well as protein-protein interactions, where extremely high sensitivity is a primary concern. Beta testing has been successfully conducted in several customer laboratories in the U.S., Australia, Japan, and Europe.
Availability
The new ProteOn GLH sensor chip can be ordered for immediate delivery. For more information on Bio-Rad's GLH sensor chip visit www.bio-rad.com/proteininteraction.
Find further information in Bio-Rad bulletin number 5679 entitled, "Applications of the ProteOn GLH Sensor Chip: Interactions Between Proteins and Small Molecules," which is available at www.bio-rad.com/proteininteraction.
About Bio-Rad
Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,300 people globally and had revenues approaching $1.5 billion in 2007. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, as updated by subsequent place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements. Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.